ArticleCancer discovery2020
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.Cancer discovery · 2021Trial
- Dual SYK-HDAC Inhibitor Elicits Striking Efficacy against Acute Myeloid Leukemia: Rational Design, Synthesis, and Biological Evaluation.Journal of medicinal chemistry · 2026Article
- Metabolomics profiling of acute myelogenous leukemia patients to identify systemic differences associated with in vitro sensitivity to SYK inhibitors.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Article
- Inflammatory signaling pathways play a role in SYK inhibitor resistant AML.Scientific reports · 2025Article
- Multi-scale signaling and tumor evolution in high-grade gliomas.Cancer cell · 2024Article
- Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment.Hematology reports · 2023Review
- Article
- LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1.Nature communications · 2023Article
- Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition.Cancer research · 2023Article
- Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition.International journal of molecular sciences · 2022Article
- Integrating Single-Cell Transcriptome and Network Analysis to Characterize the Therapeutic Response of Chronic Myeloid Leukemia.International journal of molecular sciences · 2022Article
- Article
- Review
- Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia.Blood advances · 2022Article
- Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.Signal transduction and targeted therapy · 2022Article
- Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.Haematologica · 2021Article
- Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.International journal of molecular sciences · 2021Article
- Decoding the Mechanism of Shen Qi Sha Bai Decoction in Treating Acute Myeloid Leukemia Based on Network Pharmacology and Molecular Docking.Frontiers in cell and developmental biology · 2021Article
- SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.Cell death & disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 2 countries.
Anjali CremerDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID https://orcid.org/0000-0003-4701-842X
Jana M EllegastDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Gabriela AlexeDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID https://orcid.org/0000-0002-5668-6297
Elizabeth S FrankDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID https://orcid.org/0000-0001-9268-5104
Linda RossDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
S Haihua ChuDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Yana PikmanDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID https://orcid.org/0000-0002-5336-0216
Amanda RobichaudDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Amy GoodaleThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Björn HäuplUniversity Hospital Frankfurt, Department of Hematology/Oncology, Frankfurt/Main, Germany.
Sebastian MohrUniversity Hospital Frankfurt, Department of Hematology/Oncology, Frankfurt/Main, Germany.
Arati V RaoGilead Sciences Inc., Foster City, California.
Alison R WalkerDepartment of Internal Medicine, Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
James S BlachlyDepartment of Internal Medicine, Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.ORCID https://orcid.org/0000-0002-4275-5562
Federica PiccioniThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Scott A ArmstrongDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
John C ByrdDepartment of Internal Medicine, Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio.
Thomas OellerichUniversity Hospital Frankfurt, Department of Hematology/Oncology, Frankfurt/Main, Germany. kimberly_stegmaier@dfci.harvard.edu thomas.oellerich@kgu.de.
Kimberly StegmaierDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. kimberly_stegmaier@dfci.harvard.edu thomas.oellerich@kgu.de.
Dana-Farber Cancer Institute · USBroad Institute · USGoethe University Frankfurt · DEThe Ohio State University · USGilead Sciences (United States) · US
Funding
Targeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI GRAUBERT, TIMOTHY A · 2017 to 2021
$10.6MIntegrating Transforming Approaches to Identify and Target New Vulnerabilities in CancerR35CA210030 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2016 to 2022
$7.3MTargeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6MTargeting mitochondrial one carbon folate metabolism for novel T-cell acute lymphoblastic leukemia therapyK08CA222684 · NCI · DANA-FARBER CANCER INST · PI PIKMAN, YANA · 2018 to 2022
$886kNCI NIH HHS K08 CA222684NCI NIH HHS P50 CA206963NCI NIH HHS R35 CA197734NCI NIH HHS R35 CA210030
Abstract
Spleen tyrosine kinase (SYK) is a nonmutated therapeutic target in acute myeloid leukemia (AML). Attempts to exploit SYK therapeutically in AML have shown promising results in combination with chemotherapy, likely reflecting induced mechanisms of resistance to single-agent treatment
Indexed as
AnimalsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesCell Line, TumorClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicDiphenylamineDrug Resistance, NeoplasmDrug SynergismFemaleGene Expression Regulation, LeukemicHumansIndazolesLeukemia, Myeloid, AcuteMAP Kinase Signaling SystemMice6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amineBenzamidesDiphenylamineIndazolesMAPK1 protein, humanmirdametinibMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase KinasesMorpholinesProtein Kinase InhibitorsProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humanPyrazinesSyk KinaseSYK protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.